Platelet transfusion is widely used to prevent bleeding in patients with severe thrombocytopenia. The maximal storage duration of platelet concentrates is usually 5 days, due to the platelet storage lesion that impairs their functions when stored for longer times. Some of the morphological and biochemical changes that characterize this storage lesion are reminiscent of cell death by apoptosis. The present study analyzed whether proteins involved in nucleated cell apoptosis could play a role in the platelet storage lesion. Storage of leukocyte-depleted platelets obtained by apheresis is associated with a late and limited activation of caspases, mainly caspase-3. This event correlates with an increased expression of the pro-apoptotic BH3-only protein Bim in the particulate fraction and a slight and late release of the pro-apoptotic mitochondrial protein Diablo/Smac in the cytosol. Platelets do not express the death receptors Fas, DR4 and DR5 on their plasma membrane, while the expression of the decoy receptor DcR2 increases progressively during platelet storage. Addition of low concentrations of the cryoprotector dimethylsulfoxide accelerates platelet caspase activation during storage, an effect that is partially prevented by the caspase inhibitor z-VAD-fmk. Altogether, DcR2 expression on the plasma membrane is an early event while caspase activation is a late event during platelet storage. These observations suggest that caspases are unlikely to account for the platelet storage lesion. As a consequence, addition of caspase inhibitors may not improve the quality of platelet concentrates stored in standard conditions. Leukemia (2001) 15, 1572-1581.
Introduction
Platelets are anucleated blood cells derived from bone marrow megakaryocytes. These cells, whose life-span in the circulation is about 10 to 12 days, are critical for normal hemostasis. Transfusion of platelet concentrates is widely used to prevent bleeding in patients with severe thrombocytopenia as a consequence of various diseases or cytotoxic treatments. The two main methods currently used to prepare platelet concentrates from healthy donors are the buffy coat (multiple donors) and the apheresis (single donor) methods. 1 In some countries, leukocyte depletion of platelet concentrates is performed systematically by using a filtration method. In France, the number of residual leukocytes per bag must be lower than 1 × 10 6 per concentrate that otherwise contains more than 2 × 10 11 platelets. Then, platelet concentrates are suspended in plasma and stored in gas-permeable plastic containers with gentle and continuous agitation on a horizontal reciprocator at a stable temperature of 20-24°C. The maximal storage duration after whole blood withdrawal is 5 days.
leading to impaired functions. 3 The conditions of harvesting, processing and storage influence these platelet changes that can be associated with a decrease in post-transfusion recovery in vivo. The platelet storage lesion can be identified by a variety of in vitro tests. The thin discoid shape of circulating platelets is gradually lost within storage to become spherical or dendritic while the size of platelets decreases as a consequence of fragmentation into microvesicles. 4 Visual observation of the swirling phenomenon is the simplest way to identify these platelet shape changes. Altered metabolic activity, as indicated by pH changes, increased lactate production and decreased glucose consumption, as well as lactate dehydrogenase (LDH) release, also reflect the conditions of storage. 3 Many of the other changes which take place in platelets during their storage are similar to the activation of fresh platelets, although they occur much more slowly (several days compared to a few seconds) and are partially reversible. Both activated and stored platelets undergo ␣-granule release, as demonstrated by expression of CD62P (also termed Pselection) on the plasma membrane and release of cleaved CD62P in the plasma. [5] [6] [7] They also demonstrate critical plasma membrane changes such as externalization of phosphatidylserine that serves as the major surface procoagulant for assembly of the prothrombinase complex in the coagulation pathway. 8 Several of the events associated with platelet activation are reminiscent of cell death by apoptosis. 9 Two main pathways have been shown to lead to apoptosis. The intrinsic pathway involves the release of pro-apoptotic molecules such as cytochrome c (cyt c), 10, 11 apoptosis-inducing factor (AIF), 12 and Diablo/Smac 13, 14 from the mitochondrial intermembrane space under the control of pro-apoptotic and anti-apoptotic proteins of the Bcl-2 family. Once in the cytosol, cytochrome c, in the presence of ATP, induces oligomerization of the adaptor molecule Apaf-1 (apoptosis protein activating factor-1) that, in turn, recruits and activates caspase-9 and the downstream cascade of effector caspases such as caspase-3. 15 The extrinsic pathway involves plasma membrane death receptors that, upon binding of their specific ligand, recruit the adaptor molecule FADD (Fas associated death domain) and the initiator caspase designated caspase-8 in a death-inducing signaling complex. Activated caspase-8, either directly or through the release of mitochondrial proapoptotic molecules, activates the cascade of effector caspases. 16, 17 Caspases are a family of cysteine aspartate proteases that are synthesized as proenzymes and must be cleaved at aspartate residues to be activated. Effector caspases cleave a limited number of intracellular proteins, leading to the dismantling of the cells that characterizes apoptotic cell death. 18, 19 Several observations suggested a role for these apoptotic pathways in the platelet storage lesion: (1) cell shrinkage, release of microvesicules and phosphatidylserine redistribution on the cell surface are observed in both activated plateDcR2 and caspases in the platelet storage lesion S Plenchette et al 1573 lets and apoptotic cells; 8, 9, 20 (2) human platelets contain caspase-3 and caspase-9, the adaptor molecule Apaf-1 and several proteins of the Bcl-2 family of death regulators; 9, 21, 22 (3) addition of cytochrome c to cell-free extracts from platelets recapitulates the cytosolic events of apoptosis; 22 (4) exposure of platelets to ionomycin, a calcium ionophore, increases expression of Bax, a pro-apoptotic member of the Bcl-2 family in these cells; 9 and (5) the nucleus was demonstrated not to be an absolute requirement for apoptosis induction. 9, [22] [23] [24] Based on these observations, we investigated whether proteins involved in apoptosis regulation of nucleated cells could play a role in platelet storage lesion.
Materials and methods

Antibodies and chemicals
The polyclonal antibody (Ab) Diablo/Smac, the monoclonal Abs M271 (DR4), M413 (DR5), M431 (DcR1) and M445 (DcR2), and the monoclonal Ab RIK-2 (TRAIL) were kindly provided by Dr Wang (Howard Hughes Medical Institute, Dallas, TX, USA), Dr Kubin (Immunex Corporation, Seattle, WA, USA) and Dr Yagita (Juntendo University, Tokyo, Japan), respectively. Others Abs used were directed against procaspase-2 and HSC 70 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), Bcl-X L , procaspase-7 and procaspase-3 (Transduction Laboratories, Lexington, KY, USA), caspase-3-p19 and p17 subunits (New Englands Biolabs, Yvellines, France), Bax and procaspase-8 (Immunotech, Marseille, France), procaspase-9 and cytochrome c (Pharmingen, La Jolla, CA, USA), Bim and procaspase-10 (Calbiochem, La Jolla, CA, USA), poly(ADP-ribose) polymerase (PARP) (Boehringer-Mannheim, Meylan, France), calnexin (Stressgen, Victoria, Canada), Bid (R&D Systems, Oxon, UK) and Bcl-2 (Dako, Trappes, France). Dimethylsulfoxide (DMSO) and etoposide were purchased from Sigma-Aldrich (Saint-Quentin, Fallavier, France). z-VAD-fmk (benzoyloxy carbonyl-Val-AlaAsp(OMe)-fluoromethylketone) was obtained from R&D Systems. Fluorogenic peptides benzyloxy-carbonyl-Val-Asp-ValAla-Asp-7-amino-4-trifluoro methyl coumarin (z-VDVAD-
, and Ac-Leu-Glu-His-Asp-AFC (Ac-LEHD-AFC) were purchased from Calbiochem (Meudon, France).
Cell line and culture conditions
The U937 human leukemic cell line was obtained from the American Type Culture Collection (Manassas, VA, USA) and grown in suspension culture at 37°C in the presence of 5% CO 2 in RPMI-1640 medium supplemented with 10% (v/v) heat-inactived fetal bovine serum, 2 mmol/l l-glutamine. Cell culture products were purchased from Biowhittaker (Fontenay-sous-bois, France). To ensure an exponential growth, cells were resuspended in fresh medium 24 h before each treatment.
Preparation of platelets
Platelet concentrates were obtained at the Bourgogne-Franche-Comté Transfusion Center from healthy donors with their Leukemia informed consent. Platelet concentrate aphereses were performed by using a Cobe Spectra cell separator (Cobe, Denver, CO, USA) with LRS (Leuko Reduction System) that allows efficient leukodepletion. Platelet number and purity were assessed by using the Unopette collection system and phase contrast microscopy. The extent of white blood cell contamination was additionally evaluated by cell counting and thickwell hemocytometer counting with propidium iodide. The mean number of platelets per bag was 6 × 10 11 and the mean number of white blood cells was always lower than 1 × 10 6 per bag. In addition, no measurable interleukin-8 (IL-8) was detected in the bag, as monitored by enzyme-linked immunosorbent assay (ELISA; R&D Systems) during the storage, up to 11 days. Platelets were stored in standard conditions (diluted in plasma containing acid-citrate-dextrose (ACD)-type A anticoagulant solution at 22°C on a rolling agitator). Aliquots were taken aseptically at various time after the beginning of storage and centrifuged at 2 400 r.p.m. for 15 min at room temperature. The pellet was washed twice in a modified Hepes tyrodealbumin 0.35% buffer, then adjusted to a concentration of 3-6 × 10 8 /ml in modified Hepes tyrode-albumin 0.35% buffer for further analyses.
Platelet lysate preparation and subcellular fractionation
Approximately 3 × 10 10 platelets were diluted in a volume of ice-cold hypotonic lysis buffer (20 mmol/l Tris, pH 7.4, 1 mmol/l EGTA, 20 g/ml leupeptin, 1 mmol/l sodium orthovanadate, 2 g/ml aprotinin, 100 mol/l phenylmethylsulfonylfluoride (PMSF)) and incubated on ice for 10 min. After vortexing, half of the lysate was diluted with an equal volume of hypotonic buffer, yielding the whole cell lysate fraction. The subcellular fractionation of platelets was performed by using a previously described protocol with some modifications. 25 Briefly, the remaining half lysate was centrifuged at 100 000 g for 30 min at 4°C. The pellet was resuspended in a volume of hypotonic lysis buffer and centrifuged again at 100 000 g for 30 min at 4°C. Supernatants from the two centrifugations were pooled and yielded the S100 or cytosolic fraction. Pellets were resuspended in a similar volume of lysis buffer and yielded the 'particulate fraction'. These samples were frozen at −80°C until analyzed.
Western blot analysis
Protein concentration of cellular lysates was determined by using the Bradford reagent (Bio-Rad Laboratories, Ivry-surSeine, France). Fifty g aliquots of each protein sample were incubated in loading buffer (125 mmol/l Tris-HCl, pH 6.8, 10% beta-mercaptoethanol, 4.6% sodium dodecyl sulfate (SDS), 20% glycerol and 0.003% bromophenol blue) and boiled for 3 min. Protein was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE; 12% polyacrylamide), and transferred by electroblotting to polyvinylidene difluoride membranes (BioRad). Immunoblots were pre-incubated with blocking solution (0.1% Tween 20 in phosphate-buffered saline (PBS) (TPBS), 7% non-fat milk) overnight at 4°C. Membranes were then incubated for 4 h at room temperature with the corresponding primary Abs in TPBS, washed three times for 10 min, then incubated for 30 min at room temperature with horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit Abs (Jackson Immuno-Research Laboratories, West Grove, PA, USA), and then washed three times for 10 min in TPBS. Immunoblots were revealed using an enhanced chemoluminescence (ECL) kit (Amersham, Les Ulis, France).
Caspase activity or fluorometric assays
Platelets were lysed in a volume of cold lysis buffer (40 mmol/l sodium-glycerophosphate, 50 mmol/l NaCl, 2 mmol/l MgCl 2 (6H 2 O), 5 mmol/l EGTA, 10 mmol/l Hepes, pH 7) supplemented with protease inhibitors (1 g/ml aprotinin, 1 g/ml leupeptin, 1 mmol/l PMSF, 2 mmol/l dithiothreitol (DTT)), frozen at −80°C for at least 15 min, then centrifuged at 10 000 r.p.m. at 4°C for 8 min. The supernatant containing the solubilized proteins was stored at −80°C. Protein concentration was measured as described above. Caspase activity was measured in a 96-well microplate by incubating 100 g of proteins with 5 mmol/l of substrate in the reaction buffer (100 mmol/l Hepes, pH 7, 1 mmol/l EDTA, 0.1% CHAPS, 10% glycerol, 100 mmol/l DTT -final volume 100 l). 
Monitoring of the platelet storage lesion
pH, pO 2 and pCO 2 were measured by using the Rapidlab 860 Bayer Diagnostics (Sudbury, UK) system while glucose and LDH concentrations were determined by using the VITROS 750 system (Ortho Clinical Diagnostics, Rochester, NY, USA). Soluble P-selectin concentration was measured by a commercially available ELISA kit (R&D Systems). Analysis of platelet membrane antigens (CD42b, CD61, CD62P) and death receptors (DR4, DR5, DcR1, DcR2) was performed by using the cytoquant platelet kit (Diagnostica Stago, France). Twenty l of a diluted platelet sample (2 × 10 6 platelets/ml) were incubated for 10 min at room temperature with a mouse monoclonal Ab, then incubated for 10 min in the dark at room temperature with a rabbit polyclonal anti-mouse immunoglobulin Ab conjugated to fluorescein isothiocyanate. After washing, platelets were resuspended in 1 ml buffer and analyzed using a FACScalibur flow cytometer (Becton Dickinson, Le Pont de Claix, France).
Effect of Z-VAD-fmk on the platelet storage lesion
Each platelet concentrate studied was aseptically divided into three bags and stored in standard conditions in the absence or presence of the vehicle (dimethylsulfoxide or methanol), either alone or with z-VAD-fmk (50 mol/l), added every 3 days (days 1, 4, 7 and 10). The final concentration of the vehicle never exceeded 1%. Platelet bags were stored in standard conditions and samples were taken aseptically at various storage times.
Results
Platelets express several procaspases in the cytosolic and/or particulate fractions
We first confirmed by Western blotting the previous identification of procaspase-2L, 26 procaspase-3, 21,22,26 procaspase-8 26 and procaspase-9 22 in lysates of fresh human platelet concentrates. We also detected the expression of procaspase-7 and procaspase-10 ( Figure 1 ). Compared to the U937 human leukemic cell line, used as a positive control, procaspase-9 and procaspase-3 appeared to be highly expressed in platelets while procaspase-10 was barely identified in these cells. Some procaspases have been previously detected in the mitochondria and other cellular organelles. 27, 28 Therefore, by using a previously described method that separates two subcellular fractions, 26 we compared the expression of these six procaspases in the cytosolic and the particulate fraction of human platelets. Procaspase-10 could not be detected in the cytosolic fraction, even when the blots were exposed for a longer time (not shown), while the other five enzymes were detected in the two subcellular fractions (Figure 1 ).
Caspases are only slightly activated during platelet storage
We then analyzed whether caspase activation was part of the platelet storage lesion. For this purpose, platelets obtained by apheresis were leukocyte depleted, then stored in standard conditions for up to 11 days. Platelet storage was associated with previously described changes that characterize the platelet storage lesion such as drop of pH and pCO 2 and increase in pO 2 lactate, LDH and soluble P-selectin levels. 3 Flow cytometry analyses also indicated a storage-related increase in CD62P (GMP-140 or P-selectin) expression while CD42b
Figure 1
Western blot analysis of indicated procaspases (numbers: molecular weights in kDa) in fresh human platelet lysates. U937 human leukemic cells were used as a positive control (Co). T indicates total cell lysates, C the cytosolic fraction and P the particulate fraction, respectively. One representative of at least three independent experiments from distinct donors is shown. Metabolic changes and plasma membrane markers were studied at days 1, 6 and 11 after the beginning of storage. Plasma membrane markers were studied by flow cytometry. Soluble P-selectin was measured in platelet suspension medium by ELISA. AS, antigenic site. Mean ± s.d. of at least three independent experiments.
(gpIb) expression decreased and CD61 (gpIIIa) expression remained almost unchanged (Table 1) . These results were in accordance with previously published analyses of platelets stored in standard conditions.
3,29
At various times after the beginning of storage, we prepared whole cell lysates as well as lysates from the cytosolic and particulate platelet fractions. The 116-kDa nuclear enzyme, PARP, that can be identified in U937 leukemic cells, was not detected in platelet lysates, suggesting the lack of contamination of platelet concentrates by nucleated cells (Figure 2a) . We also checked IL-8 level in platelet concentrate units since apoptosis of residual white blood cells in these units was recently associated with the release of this cytokine. 30 No IL-8 was detected in platelet concentrates stored for up to 11 days (not shown). To determine the quality of subcellular fractionation, we used Abs against calnexin whose expression was shown to be limited to the endoplasmatic reticulum. 31 Calnexin was not detected in the cytosolic fraction (Figure 2a) .
Immunoblot experiments did not identify significant storage-related change in the level of expression of the six procaspases studied in whole platelet extracts nor in the cytosolic and particulate subcellular fractions. Again, procaspase-10 could not be detected in the cytosolic fraction of these cells (Figure 2a) . However, overexposure of the caspase-3 blot suggested a partial cleavage of the 32 kDa procaspase-3 to a p21 fragment that remained limited to the cytosolic fraction (not shown). By using another anti-caspase-3 Ab, cleavage of the proenzyme to a p19 and a p17 active fragments was identified in whole platelet lysates at day 11 ( Figure 2b) .
To further determine whether caspases could be activated during platelet storage, we measured the ability of platelet lysates prepared at various time-points after collection to cleave peptide substrates that mimick the target site of the studied enzymes. These experiments identified a progressive increase in Ac-DEVD-AMC cleavage activity (measuring mainly caspase-3 and -7 activity) and, to a lesser extent, an increase in z-VDVAD-AFC (caspase-2) and Ac-LEHD-AFC (caspase-9) cleavage activities. No significant cleavage of other caspase substrates could be identified up to 11 days after platelet collection ( Figure 3) . These results were confirmed by comparing a series of 10 distinct platelet concentrates at day 1 and day 5 of storage. These experiments again identified a slight increase in Ac-DEVD-AMC cleavage activity between day 1 and day 5, but failed to identify any significant change in the cleavage of other caspase substrates (Figure 4) . Altogether, Leukemia these results suggested that platelet storage lesion was associated with the late activation of a limited number of caspases, including caspase-3.
Platelet storage lesion is associated with a late increase in Bim expression in the particulate fraction
Many of the signals leading to caspase activation are regulated by the Bcl-2 protein family. Upon apoptotic stimuli, pro-apoptotic molecules of this family can translocate to intracellular membranes where they bind to and neutralize Bcl-2 and its anti-apoptotic homologs. 32, 33 While we failed to detect any Bcl-2 protein in platelet cell lysates, as previously described, 34 the Bcl-2 homolog Bcl-X L was highly expressed in these cells, both in the cytosolic and the particulate fractions, and its expression remained unchanged during platelet storage (Figure 5a ). The pro-apoptotic proteins Bax, Bid and Bim were also detected in whole cell lysates as well as in the particulate and the cytosolic fractions of these cells. While the expression of Bax and Bid remained unchanged during storage, Bim appeared to partly translocate from the cytosolic to the particulate fraction of platelets at day 11 of storage ( Figure 5a and b).
Platelet storage lesion is associated with a slight release of Diablo/Smac in the cytosol
Pro-apoptotic members of the Bcl-2 family such as Bim can cause the release of cytochrome c and other pro-apoptotic molecules from mitochondria into the cytosol whereas antiapoptotic members of this family such as Bcl-X L inhibit this release. 33 We therefore looked at the expression of cytochrome c and the other pro-apoptotic mitochondrial protein Diablo/Smac in platelets and their two subcellular fractions. We observed that both proteins were expressed in platelets. Their expression was limited to the particulate fraction that contains mitochondria. We did not observe a strong storagerelated decrease in their expression in the particulate fraction, nor a significant storage-related increase in their expression in the cytosolic fraction (Figure 6a) . However, by overexposing the blots, we identified, in three independent experiments performed on three distinct platelet concentrates, the appearance
Figure 2
Caspase expression during platelet concentrate storage. (a) Western blot analysis of indicated proteins (numbers: molecular weights in kDa) in lysates from human platelets (T: total cell lysates; C: cytosolic fraction; P: particulate fraction) stored for indicated timepoints (days) in standard conditions. Untreated U937 human leukemic cell lysates were used as a positive control (Co). One representative of at least three independent experiments (distinct donors) is shown. (b) Western blot analysis of caspase-3 cleavage products (p19 and p17 active fragments) in cystosolic fractions using the polyclonal caspase-3 Ab from NEB (loading: 250 g of proteins). U937 cell lysates obtained after treatment of cells with 50 mol/l etoposide for 4 h were used as a positive control of caspase-3 activated fragments. One representative of two experiments is shown. of a faint band corresponding to Diablo/Smac in the cytosolic fraction at day 11 (Figure 6b and c) .
Increased expression of the decoy receptor DcR2 is an early marker of platelet storage lesion
Another pathway by which caspases can be activated involves the plasma membrane death receptors. It has been shown that human platelets express the mRNA encoding the cytokine TRAIL and its agonistic receptors DR4 and DR5 but neither Fas nor Fas-L. 26 As far as we know, the expression of these receptors at the surface of human platelets has never been studied. We show here that neither Fas receptor (not shown) nor TRAIL, DR4 and DR5 (Figure 7a) can be detected at the surface of human platelets, either before or after storage for
Figure 3
Caspase activities during platelet concentrate storage. Caspase activities were measured in whole cell lysates of platelets stored for indicated time-points. These lystates were incubated with the indicated fluorogenic subtrate peptides. Results are the mean ± s.d. of measurements performed in three distinct samples. up to 11 days. We also analyzed the expression of two decoy receptors of TRAIL, known as DcR1 and DcR2, whose function in TRAIL signaling remains poorly understood. 35 While DcR1 could not be detected at the surface of platelets, even after storage for 11 days, DcR2 expression was slightly expressed at the surface of fresh cells and its expression progressively increased during platelet storage (Figure 7b ). This observation suggests that DcR2 expression at the plasma membrane could be used as a new marker of platelet aging.
Platelet caspases can be activated by DMSO and this activation is prevented by the caspase inhibitor z-VAD-fmk
Several protease inhibitors were shown to yield some protective effect towards platelet storage lesion. 36 Since a slight and late but reproducible activation of caspase-3 was associated with platelet storage, we tried to determine whether the caspase inhibitor z-VAD-fmk could demonstrate some protective effect. This peptide must be solubilized in DMSO. Although its concentration in platelet concentrates remained limited (1%), DMSO demonstrated some toxicity towards platelets, as suggested by decreased swirling and changes in platelet concentrate metabolism, cell surface marker expression and P-selectin release (Table 2 ). This cytotoxic effect was associated
Figure 4
Caspase activities during platelet concentrate storage. Caspase activities were measured at day 1 and day 5 of storage in whole cell lysates of platelet concentrates from 10 distinct donors. These lysates were incubated with the indicated fluorogenic subtrate peptides. Statistical analysis was performed by using the Student's ttest for paired samples. Ac-DEVD-AFC: P = 0.06. Other substrates:
with a four-fold increase in DEVDase activity, suggesting caspase-3 activation, as soon as 5 days after platelet collection (Figure 8a ). This activation was confirmed by Western blot analysis of platelet lysates showing the appearance of p19 and p17 caspase-3 cleavage fragments and procaspase-9 expression decrease (Figure 8b) . Addition of z-VAD-fmk to DMSO prevented DEVDase activation and partially protected platelets from metabolic changes induced by DMSO alone (Figure 8a ). Similar observations were made by using methanol as z-VAD-fmk vehicle (not shown).
Discussion
Platelets express the main caspases involved in nucleated cell apoptosis, including effector enzymes such as caspase-3 and caspase-7, and initiator enzymes. The latter include caspase-9 that is involved in the intrinsic mitochondrial death pathway 37 and caspase-8 38 and caspase-2L 39 that are involved in the extrinsic death receptor-mediated apoptotic pathway. Caspase identification cannot be related to platelet concentrate
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Figure 5
Western blot analysis of Bcl-2 and related proteins. (a) Western blot analysis of indicated proteins (numbers: molecular weights in kDa) in lysates from human platelets (T: total cell lysates; C: cytosolic fraction; P: particulate fraction) stored for indicated timepoints (days) in standard conditions. Untreated U937 human leukemic cell lysates were used as a positive control. Loading was checked by using an anti-human HSC 70 monoclonal antibody. One representative of three independent experiments from distinct donors is shown. (b) The Bim/HSC 70 ratio in the particulate fraction was measured by densitometry scanning from blots shown in a.
contamination by residual nucleated cells since the PARP enzyme, which is a nuclear protein, 40 was not detected in platelet lysates. In addition, IL-8 was not identified in platelet units for up to 11 days of storage. 30 Interestingly, all the caspase zymogens but procaspase-10 are expressed in both the cytosolic and the particulate fractions of platelets. While most procaspases have been detected in the cytosol of nucleated cells, some of them were also identified in organelles, eg a fraction of procaspase-3, -2 and -9 was observed in the intermembrane mitochondrial space from various cell types 27 while caspase-7 was located in the microsomes. 41 Although the biological function of caspase compartmentalization remains poorly understood, it was suggested that sequestration of procaspases in various cellular compartments might restrain Cytosolic release of mitochondrial pro-apoptotic proteins. (a) Western blot analysis of indicated proteins (numbers molecular weights in kDa) in lysates from human platelets (T: total cell lysates; C: cytosolic fraction; P: particulate fraction) stored for indicated time-points (days) in standard conditions. Untreated U937 human leukemic cell lysates were used as a positive control. One representative of three independent experiments is shown. (b) Over-exposure of the Diablo/Smac immunoblot showing the appearance of a faint 25-kDa band in the cytosolic fraction at day 11 of storage. HSC 70 monoclonal antibody was used to check the loading. (c) The Smac/HSC 70 ratio in the cytosolic fraction was measured by densitometry scanning from blots shown in a.
their activation and separate them from their substrate in living cells.
Procaspase-3 was initially proposed to play a role in platelet activation, based on a slight increase in DEVD-pNA cleaving activity and a slight decrease in procaspase-3 expression upon stimulation with various agonists. 21 It was suggested that both caspase-dependent and caspase-independent pathways may account for apoptosis-like events associated with platelet activation such as translocation of phosphatidylserine on the outer leaflet of the plasma membrane. However, the caspase inhibitor z-VAD-fmk does not prevent phosphatidylserine exposure in activated platelets. 9, 22, 34 In addition, Wolf et al 22 demonstrated that calpain was able to process procaspase-3 and procaspase-9 at specific cleavage sites without generating the active caspase subunits and proposed that calpains, but not caspases, were responsible for apoptosis-like events during platelet activation. 42, 43 The role of caspases in platelet Platelets were stored for indicated times in the absence or presence of 0.25% DMSO, with or without z-VAD-fmk (50 mol/l) added at days 1, 4, 7 and 10. Indicated parameters as in Table 1 were studied. Results of one representative experiment are shown. aging is also controversial. Artificial aging of platelets by in vitro culture at 37°C does not activate caspase-3 while the present study confirms the recent demonstration that procaspase-3 is cleaved in its active p17 fragment upon storage for 11 days. 26 In addition, we show here that procaspase-3 cleavLeukemia age is associated with a slight increase in Ac-DEVD-AMC cleavage activity. This activity remains limited at day 5, which is the maximal legal time for shelf-life storage in most countries 2 and increases mainly from day 5 to day 11. In addition to caspases, platelets were shown to express several proteins of the Bcl-2 family. 9, 26, 34 Some of these Bcl-2-related proteins are pro-apoptotic proteins, which are present in healthy cells in a dormant form and behave as stress sensors by monitoring the integrity of vital metabolic processes. 33 One of them is the BH3 domain-only protein Bim 44 that is expressed in many hematopoietic cell types and is sequestered to cytoskeletal structures of healthy cells via association with dynein light chain LC8. 45 In response to some apoptotic stimuli, Bim is released in a caspase-independent manner from the dynein motor complex and translocates to intracellular membranes where it can initiate the caspase cascade. Bim−/− mice demonstrated a 50% drop of their platelet blood count, 46 indicating that Bim could play a role in platelet maturation. In the present study, we observed a slight increase in Bim expression in the particulate fraction of platelets at day 11 of their storage. Analysis of the storage lesion in platelets from Bim−/− mice will be required to determine whether Bim behaves as a sensor protein for platelet aging.
The main mitochondrial protein that is released upon apoptotic stimuli and activates the caspase cascade in the cytosol is cytochrome c. Such a release was observed in platelets whose aging was induced by in vitro culture at 37°C. 34 The present study failed to identify a significant release of cytochrome c from the particulate to the cytosolic fraction, up to 11 days of platelet storage. We cannot rule out a limited cytochrome c release, below the assay detection level, since a slight but reproducible increase in the expression of Diablo/Smac, another mitochondrial pro-apoptotic protein, was identified in the cytosol at day 11.
Another pathway to cell death involves a series of members of the tumor necrosis factor superfamily upon binding to their cognate receptors. One of these members is Fas-ligand whose interaction with its receptor Fas plays a role in erythropoiesis regulation. 47 Anti-Fas Abs were shown to have no effect on platelets 22 and Fas mRNA was not detected in these cells. 26 Accordingly, we failed to detect any Fas expression at the surface of these cells, suggesting that the Fas-mediated cell death pathway is not involved in the platelet storage lesion. Another key cytokine in this family is TRAIL, also known as Apo-2 ligand. 48, 49 Although the mRNA for the two distinct agonistic receptors for TRAIL, DR4 50 and DR5 51 were found in platelets, 16 we did not identify the corresponding proteins at the surface of platelets. Two additional receptors for TRAIL, designated DcR1 52 and DcR2, 53 differ from DR4 and DR5 by their cytoplasmic domain and do not mediate apoptosis upon ligation. 54 Although DcR1 and DcR2 were initially proposed to act as decoy receptors and to determine whether a cell is resistant or sensitive to TRAIL, 35 their biological functions remain to be identified. Nevertheless, increased expression of DcR2 at the surface of aging platelets identified in the present study defines a new and early marker of platelet storage lesion.
By testing the ability of z-VAD-fmk to prevent the activation of caspases during shelf storage, we observed that low concentrations of DMSO, which is the vehicle used to solubilize the caspase inhibitor, accelerated the appearance of the platelet storage lesion markers. Interestingly, the toxic effect of DMSO was associated with an activation of caspase-9 and caspase-3 and was partly prevented by z-VAD-fmk. Thus, DMSO, that is used as a cryoprotector for platelet concentrate storage in liquid nitrogen, is able to activate the caspase cascade in these cells.
To summarize, the present study has shown that activation of a limited number of caspases can be detected during shelf storage and correlates with Bim translocation to the particulate fraction of these cells. However, the late occurrence of caspase activity and its limited intensity indicate that caspase inhibitors may not improve the quality of platelet concentrates stored in standard conditions. On the other hand, the ability of caspase inhibitors 56 to improve the quality of platelet concentrates frozen in the presence of DMSO requires investigation. Lastly, increased expression of DcR2 at the surface of stored platelets defines a new marker of the platelet storage lesion.
